Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific antibody + di-DTPA-131I
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A pretargeted radioimmunotherapy approach combining a bispecific monoclonal antibody (BsmAb) targeting carcinoembryonic antigen (CEA) and DTPA-indium complex with a radioactive di-DTPA-131I hapten. The BsmAb first localizes to CEA-expressing tumor cells, and after a clearance interval (typically 4-5 days), the radioactive hapten is administered, binding to the second specificity of the BsmAb, delivering radiation specifically to the tumor site.
Beyond the preview
Go deeper on bispecific antibody + di-DTPA-131I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific antibody + di-DTPA-131I.